Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is LENALIDOMIDE, with a corresponding US DMF Number 23410.
Remarkably, this DMF maintains an Active status since its submission on December 29, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 10, 2015, and payment made on February 23, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II